About Cipher Pharmaceuticals (TSE:DND)
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.
Industry, Sector and Symbol:
- Trailing P/E Ratio: N/A
- P/E Growth: 0
- Net Margins: 44.75%
- Return on Equity: 113.74%
- Return on Assets: 26.78%
Frequently Asked Questions for Cipher Pharmaceuticals (TSE:DND)
What is Cipher Pharmaceuticals' stock symbol?
Cipher Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "DND."
Who are some of Cipher Pharmaceuticals' key competitors?
Some companies that are related to Cipher Pharmaceuticals include Colliers International Group (CIG), Kirkland Lake Gold Ltd (NMI), Osisko Mining Corp (OBM), Royal Bank of Canada (RY), Bank of Nova Scotia (BNS), Enbridge (ENB), Canadian National Railway Company (CNR), Suncor Energy (SU), Bank of Montreal (BMO), TransCanada (TRP), BCE (BCE), Manulife Financial Corp. (MFC), Canadian Natural Resources Limited (CNQ), Canadian Imperial Bank of Commerce (CM), Thomson Reuters Corp (TRI), Great-West Lifeco (GWO), Imperial Oil Ltd (IMO) and Canadian Pacific Railway Limited (CP).
Who are Cipher Pharmaceuticals' key executives?
Cipher Pharmaceuticals' management team includes the folowing people:
- John D. Mull M.D., Chairman of the Board
- Robert D. Tessarolo, President, Chief Executive Officer
- Stephen L. Lemieux CPA, Chief Financial Officer, Secretary
- Ralph Bohrer, President and General Manager of US Business
- Joan Chypyha, President, General Manager - Canada
- Joseph Pecora, President and General Manager - USA
- Lorne Markowitz, Vice President of Sales and Marketing
- Linda Melanie Angaritis, Vice President - Global Regulatory Compliance and Quality
- Louise Blythe, Vice President - Regulatory Affairs
- Lynne Cheryl Bulger, Vice President - Medical and Clinical Affairs
How do I buy Cipher Pharmaceuticals stock?
Shares of Cipher Pharmaceuticals and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Cipher Pharmaceuticals' stock price today?
MarketBeat Community Rating for Cipher Pharmaceuticals (TSE DND)MarketBeat's community ratings are surveys of what our community members think about Cipher Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Cipher Pharmaceuticals stock can currently be purchased for approximately C$14.89.
Consensus Ratings for Cipher Pharmaceuticals (TSE:DND) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Cipher Pharmaceuticals (TSE:DND)
Analysts' Ratings History for Cipher Pharmaceuticals (TSE:DND)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Cipher Pharmaceuticals (TSE:DND)Earnings History by Quarter for Cipher Pharmaceuticals (TSE DND)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Cipher Pharmaceuticals (TSE:DND)
Current Year EPS Consensus Estimate: $0.47 EPS
Dividend History for Cipher Pharmaceuticals (TSE:DND)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Cipher Pharmaceuticals (TSE:DND)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Cipher Pharmaceuticals (TSE:DND)
Latest Headlines for Cipher Pharmaceuticals (TSE:DND)
Loading headlines, please wait.
Cipher Pharmaceuticals (DND) Chart for Monday, October, 23, 2017